CP-751,871 MK0646 BIIB022 AMG479 R1507 Linsitinib (OSI-906) XL228 Cixutumumab (IMC-A12) MEDI-573

MK0646

MK0646 is a monoclonal antibody that inhibits the insulin-like growth factor 1 receoptor (IGF-1R).  It is administered intravenously.

MK0646 is under development by Merck.  For information from the manufacturer, see the Merck website.    Currently there is little information there other than a list of trials.

There are numerous trials with this drug, but no currently recruiting trials are relevant to GIST patients.  Two trials now closed to recruitment were:

MK0646 is in a combination trial with an mTOR inhibitor, deforolimus:
A Combination Study With MK8669 (Deforolimus) and MK0646 in Patients With Advanced Cancer

MK0646 is in this single-agent Phase I trial:
Study of MK0646 in Patients With Solid Tumors